Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study.
Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, Ward R. · 2017
Read Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. by Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, Ward R. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5634543.txt.
Introduction
Pearce and co-authors report a prospective cohort study in PLoS ONE. The study tracked chemotherapy side effects in routine care. It took place across treatment centers in Australia. Patients had breast, lung, or colorectal cancer. Side effects came from patient self-reports, not clinician notes. Follow-up had a median length of 5.64 months.
Data covered 449 eligible patients. The authors report that 86 percent had at least one side effect. About 27 percent reported a grade IV side effect. Fatigue was most common, at 85 percent. Diarrhoea and constipation each reached 74 percent. Rates were much alike across cancers and side effects. Older patients reported side effects less often. The study gives Australian decision makers real-world rates.
Catalog record
| CREATOR | Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, Ward R. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study By Alison Pearce, Marion Haas, Rosalie Viney, Sallie-Anne Pearson, Philip Haywood, Chris Brown, Robyn Ward, Apar Kishor Ganti Published in: PLoS ONE DOI: 10.1371/journal.pone.0184360 ABSTRACT Aim Chemotherapy side effects are often reported in clinical trials; however, there is little evidence about their incidence in routine clinical care. The objective of this study was to describe the frequency and severity of patient-reported chemotherapy side effects in routine care across treatment centres in Australia. Methods We conducted a prospective cohort study of individuals with breast, lung or colorectal cancer undergoing chemotherapy. Side effects were identified by patient self-report. The frequency, prevalence and incidence rates of side effects were calculated by cancer type and grade, and cumulative incidence curves for each side effect computed. Frequencies of side effects were compared between demographic subgroups using chi-squared statistics. Results Side effect data were available for 449 eligible individuals, who had a median follow-up of 5.64 months. 86% of participants reported at least one side effect during the study period and 27% reported a grade IV side effect, most commonly fatigue or dyspnoea. Fatigue was the most common side effect overall (85%), followed by diarrhoea (74%) and constipation (74%). Prevalence and incidence rates were similar across side effects and cancer types. Age was the only demographic factor associated with the incidence of side effects, with older people less likely to report side effects. Conclusion This research has produced the first Australian estimates of self-reported incidence of chemotherapy side effects in routine clinical care. Chemotherapy side effects in routine care are common, continue throughout chemotherapy and can be serious. This work confirms the importance of observational data in providing clinical practice-relevant information to decision-makers. INTRODUCTION Chemotherapy is an important component of treatment for many cancers, and new anti-cancer drugs represent one of the largest areas of pharmaceutical development [1, 2]. However, the nature of chemotherapy means that while damaging cancer cells it also damages healthy cells, leading to side effects [3]. The side effects of chemotherapy affect an individual’s physical health, quality of life [4–6] and emotional state [4, 5]. The management of a side effect can include a reduction in the dose intensity of chemotherapy [7] and there is evidence that patients who receive low dose chemotherapy have reduced survival rates [8–11]. Our understanding about side effects and their frequency comes primarily from clinical trials [12]. However, this may not reflect the reality of chemotherapy side effects in routine clinical practice. For example, patients who are at risk of complications are often excluded from clinical trials, and safety monitoring may be more intensive in trials than in routine care [12]. In addition, the reporting of chemotherapy side effects in clinical trial publications is often selective, and based on the most common or most serious side effects [13, 14]. Finally, side effects in clinical trials are typically clinician reported and there is evidence that clinicians often under report the number and severity of toxicities experienced by patients [15, 16]. Observational data collected in routine clinical practice, outside clinical trials, may provide better external validity than clinical trials [17]. Previous observational studies of chemotherapy side effects have examined only a specific chemotherapy regimen [18, 19], cancer type and stage [20–23] or side effect [18, 24, 25]. There have been very few observational studies of side effects in a typical oncology practice, across a range of cancers and treatment regimens [16, 25], despite this giving data which is more representative of routine care. The Elements of Cancer Care (EOCC) study was designed as a prospective cohort study of individuals with breast, lung or colorectal cancer undergoing chemotherapy in New South Wales, Australia [26]. The EOCC study provides the opportunity to analyse self-reported side effect information to examine the experience of chemotherapy side effects in a routine care setting. By examining the frequency of self-reported side effects in the EOCC cohort, we can obtain a more accurate estimation of the incidence of side effects in the routine care setting. As well as filling a gap in the literature, these estimates are important for clinicians and policy makers, who are usually making treatment or funding decisions about care delivered in the routine care setting and will require information about the short and long term consequences of using chemotherapy. The objective of this study was to estimate the frequency and severity of patient-reported chemotherapy side effects in a routine-care setting across treatment centres in Australia. MATERIALS AND METHODS The Elements of Cancer Care study The Elements of Cancer Care (EOCC) study design has been reported elsewhere [26], but in summary the study prospectively tracked patients undergoing chemotherapy for breast, colorectal and non-small cell lung cancer (NSCLC), and utilised information from medical and chemotherapy charts, interviews and linked administrative data. The study recruited patients from 12 cancer treatment centres in New South Wales, Australia, representing metropolitan and regional settings and the public and private hospital sectors. The eligibility criteria were that patients be aged over 18 years, able to comprehend written and spoken English (or have an interpreter available), able to give informed consent, and not participating in a clinical trial. The primary data collection included medical-record reviews together with monthly patient interviews (programmed every 28 days) conducted by study field staff (medical students and research assistants) who were trained (by the study coordinator, using a training manual, initial shadowing and regular group review meetings) to conduct the research interviews. Data were collected on cancer treatment, health service utilisation, socioeconomic status, use of complementary therapy and a range of other factors (data collection instrument available upon request). Patient follow-up and data collection continued until either cessation of chemotherapy without recommencement within 30 days, patient withdrawal, or the census date was reached (June 11, 2010 for those recruited in 2009; May 5, 2011 for those recruited in 2010). Interviews continued for 6 months after recruitment, unless one of the above conditions were met. While extensive primary data were collected, the current report uses only the data items specifically relating to side effects. In relation to side effects, participants were asked in approximately monthly face to face or telephone interviews if they had experienced diarrhoea, vomiting, chest pain or angina, constipation, dyspnoea, fatigue, mucositis, pain or rash. These side effects were selected on the basis that they are common chemotherapy side effects which can be meaningfully reported from the patient perspective. Depression and anxiety were captured in the quality of life instrument, and are reported elsewhere. The structured questions provided the list of side effects with examples of each grade according to the NCI Common Toxicity Criteria version 4 [27] adapted to plain English (see S1 Tables for wording used). Although not a formally validated instrument, there is evidence that adapted versions of the Common Toxicity Criteria for completion by patients result in ratings consistent with those provided by their clinicians [16]. Patient written and informed consent was obtained through a face-to-face interview with study field staff. The St Vincent’s Hospital Human Research Ethics Committee approved the primary data collection. Site-specific approvals were obtained from each of the participating centres. The study is registered at Research Data Australia (Identifier 004:273).